LEADER 00000cam  22006138i 4500 
001    on1345278931 
003    OCoLC 
005    20230407213018.0 
006    m     o  d         
007    cr ||||||||||| 
008    220523t20232023cau     ob    001 0 eng   
010      2022023733 
020    9780520388727|q(electronic book) 
035    (OCoLC)1345278931 
037    22573/cats1755865|bJSTOR 
040    DLC|beng|erda|cDLC|dOCLCF|dSNM|dYDX|dUKKNU|dJSTOR 
042    pcc 
049    CKEA 
050 00 HD9666.4 
082 00 338.4/761510973|223/eng/20220919 
100 1  Roy, Victor,|d1986-|eauthor. 
245 10 Capitalizing a cure :|bhow finance controls the price and 
       value of medicines /|cVictor Roy. 
263    2301 
264  1 Oakland, California :|bUniversity of California Press,
       |c[2023] 
264  4 |c©2023 
300    1 online resource 
336    text|btxt|2rdacontent 
337    computer|bc|2rdamedia 
338    online resource|bcr|2rdacarrier 
347    data file|2rda 
504    Includes bibliographical references and index. 
505 0  Preface : pandemics, Wall Street, and the value playbook -
       - Introduction : the politics of drug pricing and the 
       value of a cure -- Capitalizing science : public knowledge
       into pharmaceutical assets -- Capitalizing drugs : 
       shareholder power and the cannibalizing company -- 
       Capitalizing health : the struggle over value and 
       treatment access -- From financialization to public 
       purpose for health -- Conclusion : reckoning with 
       pharmaceutical value in crisis times. 
520    "Capitalizing a Cure takes us into the struggle over 
       accessing a medical breakthrough to investigate the power 
       of finance over business, biomedicine, and public health. 
       When sofosbuvir-based medicines launched in 2013, they 
       promised a cure for millions of patients worldwide with 
       hepatitis C. But their sticker shock-the drug was dubbed 
       "the $1,000-a-day pill"-intensified a global debate over 
       the pricing of new medicines. Weaving extensive historical
       research with insights from political economy and science 
       and technology studies, Victor Roy demystifies an oft-
       missed dynamic in this debate: the reach of financialized 
       capitalism into how medicines are made, priced, and 
       valued. His account travels between public and private 
       labs, Wall Street and corporate boardrooms, public health 
       meetings and health centers to trace the ways sofosbuvir-
       based medicines became financial assets dominated by 
       strategies of speculation and extraction at the expense of
       access and care. Provocative and sobering, this book 
       illuminates the harmful impact of allowing financial 
       markets to supersede democracy and human health and points
       to the necessary work of building more equitable futures"-
       -|cProvided by publisher. 
588    Description based on print version record and CIP data 
       provided by publisher; resource not viewed. 
610 20 Gilead Sciences (Firm) 
610 27 Gilead Sciences (Firm)|2fast|0(OCoLC)fst01575361 
650  0 Drugs|xPrices|zUnited States. 
650  0 Pharmaceutical industry|xEconomic aspects|zUnited States. 
650  0 Drug development|xEconomic aspects|zUnited States. 
650  0 Sofosbuvir|xPrices|zUnited States. 
650  0 Hepatitis C|xTreatment|xPrices|zUnited States. 
650  7 Business & Economics / Industries / Healthcare.|2bisacsh 
650  7 Medical / Ethics.|2bisacsh 
650  7 Social Science / Sociology.|2bisacsh 
650  7 Drugs|xPrices.|2fast|0(OCoLC)fst00898879 
650  7 Pharmaceutical industry|xEconomic aspects.|2fast
       |0(OCoLC)fst01060138 
651  7 United States.|2fast|0(OCoLC)fst01204155 
776 08 |iPrint version:|aRoy, Victor, 1986-|tCapitalizing a cure
       |dOakland, California : University of California Press, 
       [2023]|z9780520388710|w(DLC)  2022023732 
914    on1345278931 
947    MARCIVE Processed 2023/08/03 
994    92|bCKE